These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clostridium difficile colitis: review of the therapeutic approach. Joseph J; Singhal S; Patel GM; Anand S Am J Ther; 2014; 21(5):385-94. PubMed ID: 22990077 [TBL] [Abstract][Full Text] [Related]
5. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Nelson RL; Kelsey P; Leeman H; Meardon N; Patel H; Paul K; Rees R; Taylor B; Wood E; Malakun R Cochrane Database Syst Rev; 2011 Sep; (9):CD004610. PubMed ID: 21901692 [TBL] [Abstract][Full Text] [Related]
6. Recurrent Clostridium difficile infection: what are the treatment options? van Nispen tot Pannerden CM; Verbon A; Kuipers EJ Drugs; 2011 May; 71(7):853-68. PubMed ID: 21568363 [TBL] [Abstract][Full Text] [Related]
7. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Nelson R Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768 [TBL] [Abstract][Full Text] [Related]
8. Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials. Igarashi Y; Tashiro S; Enoki Y; Taguchi K; Matsumoto K; Ohge H; Suzuki H; Nakamura A; Mori N; Morinaga Y; Yamagishi Y; Yoshizawa S; Yanagihara K; Mikamo H; Kunishima H J Infect Chemother; 2018 Nov; 24(11):907-914. PubMed ID: 30170735 [TBL] [Abstract][Full Text] [Related]
9. Therapy for Clostridium difficile infection - any news beyond Metronidazole and Vancomycin? Manthey CF; Eckmann L; Fuhrmann V Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1239-1250. PubMed ID: 28766951 [TBL] [Abstract][Full Text] [Related]
10. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Di X; Bai N; Zhang X; Liu B; Ni W; Wang J; Wang K; Liang B; Liu Y; Wang R Braz J Infect Dis; 2015; 19(4):339-49. PubMed ID: 26001980 [TBL] [Abstract][Full Text] [Related]
11. New and emerging therapies in treatment of Clostridium difficile infection. Goyal H; Perisetti A; Rehman MR; Singla U Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):589-597. PubMed ID: 29521664 [TBL] [Abstract][Full Text] [Related]
12. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Cornely OA; Miller MA; Louie TJ; Crook DW; Gorbach SL Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S154-61. PubMed ID: 22752865 [TBL] [Abstract][Full Text] [Related]
13. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742 [TBL] [Abstract][Full Text] [Related]
14. Best strategies in recurrent or persistent Clostridium difficile infection. Cocanour CS Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157 [TBL] [Abstract][Full Text] [Related]
15. Treatment of Clostridium difficile infections. Soriano MM; Johnson S Infect Dis Clin North Am; 2015 Mar; 29(1):93-108. PubMed ID: 25573676 [TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Polivkova S; Krutova M; Capek V; Sykorova B; Benes J Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906 [TBL] [Abstract][Full Text] [Related]
17. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862 [TBL] [Abstract][Full Text] [Related]
18. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Warren CA; van Opstal E; Ballard TE; Kennedy A; Wang X; Riggins M; Olekhnovich I; Warthan M; Kolling GL; Guerrant RL; Macdonald TL; Hoffman PS Antimicrob Agents Chemother; 2012 Aug; 56(8):4103-11. PubMed ID: 22585229 [TBL] [Abstract][Full Text] [Related]
19. Risk factors and outcomes of Clostridium difficile infection in hospitalized patients. Lee HY; Hsiao HL; Chia CY; Cheng CW; Tsai TC; Deng ST; Chen CL; Chiu CH Biomed J; 2019 Apr; 42(2):99-106. PubMed ID: 31130254 [TBL] [Abstract][Full Text] [Related]
20. Lack of adherence to SHEA-IDSA treatment guidelines for Clostridium difficile infection is associated with increased mortality. Patel I; Wungjiranirun M; Theethira T; Villafuerte-Galvez J; Castillo N; Akbari M; Alonso CD; Leffler DA; Kelly CP J Antimicrob Chemother; 2017 Feb; 72(2):574-581. PubMed ID: 28115504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]